ALLMedicine™ Anti-xa Assay Center
Research & Reviews 10 results
https://doi.org/10.1007/s40262-022-01108-3
Clinical Pharmacokinetics; Zhang F, Chen X et. al.
Mar 23rd, 2022 - Rivaroxaban is a novel oral anticoagulant widely used for thromboprophylaxis in patients with non-valvular atrial fibrillation (NVAF). The present study aimed to develop a population pharmacokinetic (PPK) model for rivaroxaban in Chinese patients ...
https://doi.org/10.1007/s00228-020-02896-y
European Journal of Clinical Pharmacology; Suzuki S, Yamashita T et. al.
May 27th, 2020 - To investigate the distribution of plasma apixaban levels and their relationships with clinical outcomes in elderly patients with atrial fibrillation (AF). The J-ELD AF Registry is a multicenter prospective observational study of Japanese non-valv...
https://doi.org/10.1111/ijlh.13202
International Journal of Laboratory Hematology REFERENCES; Lessire S, Dincq AS et. al.
Apr 17th, 2020 - Estimation of residual apixaban plasma concentrations may be requested in the management of emergencies. This study aims at assessing the performance of specific anti-Xa assays calibrated with apixaban on real-life samples with low apixaban plasma...
https://doi.org/10.1007/s00380-019-01501-2
Heart and Vessels; Suzuki S, Morishima Y et. al.
Sep 16th, 2019 - Direct oral anticoagulants, including edoxaban, primarily do not need routine monitoring of the anticoagulant effect. However, extremely high/low plasma concentrations of edoxaban (PC-Ed) should be properly evaluated, especially when patients unde...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404908
The American Journal of Geriatric Psychiatry : Official J... Mischoulon D, I Okereke O et. al.
Jul 23rd, 2019 - Background During treatment with direct oral anticoagulants ( DOAC ), coagulation assessment is required before thrombolysis, surgery, and if anticoagulation reversal is evaluated. Limited data support the accuracy of DOAC -specific coagulation as...
